COMPASS THERAPEUTICS INC
CMPXNASDAQTrading Snapshot
- Day Range
- $2.18 – $2.22
- 52-Week Range
- $1.61 – $6.88
- Volume
- $4.03B
- Avg Volume
- $5.12B
- Shares Outstanding
- 180.1M
- Next Earnings
- Sep 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $29M
- Last Q Revenue
- $7M
- P/E Ratio
- -5.3
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.39
- Dividend Yield
- 0.00%
Why Investors Own CMPX
- ✓High-growth profile — revenue up +14.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 65% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About COMPASS THERAPEUTICS INC
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Piper Sandler Maintains Overweight on Compass Therapeutics, Raises Price Target to $6
Piper Sandler analyst Biren Amin maintains Compass Therapeutics (NASDAQ:CMPX) with a Overweight and raises the price target from $4 to $6.
Compass Therapeutics Q2 EPS $(0.13) Misses $(0.11) Estimate
Compass Therapeutics (NASDAQ:CMPX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 7.14 percent increase over losses of $(0.14) per share
Compass Therapeutics Abstract Accepted For Oral Presentation At Upcoming European Society For Medical Oncology Congress
Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its
Compass Therapeutics: A 50% Price Cut Hiding A Regulatory Mispricing Opportunity
Compass Therapeutics is rated Buy, with risk/reward favoring upside after a sharp post-data selloff. Click here to read more about CMPX stock.